Peptide fragment and use thereof

The peptide fragment RRRRSNRRG (SEQ ID NO: 1) enhances the efficiency of introducing foreign substances into eukaryotic cells by forming a construct that effectively crosses the cell membrane, addressing the inefficiencies of existing peptides.

JP2024165340AActive Publication Date: 2024-11-28TOAGOSEI CO LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2023081456
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-05-17
Publication Date
2024-11-28
Estimated Expiration
2043-05-17

AI Technical Summary

Technical Problem

Existing cell membrane-penetrating peptides are inefficient for introducing foreign substances such as nucleic acids into eukaryotic cells.

Method used

A peptide fragment with the amino acid sequence RRRRSNRRG (SEQ ID NO: 1) is used to create a construct that efficiently introduces foreign substances like polypeptides, nucleic acids, and drugs into eukaryotic cells by binding them to the N- or C-terminus of the peptide fragment.

Benefits of technology

The peptide fragment exhibits superior cell membrane permeability, allowing efficient introduction of foreign substances into the cytoplasm of eukaryotic cells, including mammalian cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024165340000001_ABST
    Figure 2024165340000001_ABST
Patent Text Reader

Abstract

To provide a peptide fragment exhibiting enhanced cellular membrane permeability.SOLUTION: A peptide fragment disclosed herein contains an amino acid sequence: RRRRSNRRG (SEQ ID NO: 1) and has a total number of amino acid residues of 10 or less.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure relates to peptide fragments and uses thereof. [Background technology]

[0002] Conventionally, foreign substances such as polypeptides and nucleic acids have been introduced into the cells (eukaryotic cells) of humans and other mammals to transform the characteristics of the cells (and even the tissues and organs made up of the cells) or to improve or enhance the functions of the cells.

[0003] The above-mentioned technology uses, for example, a cell-penetrating peptide (CPP) that passes through the cell membrane from the outside of the cell to introduce a foreign substance into the cytoplasm. For example, Patent Documents 1 to 3 disclose technologies for nucleic acid medicines used in the treatment of diseases, and disclose technologies for introducing nucleic acids into cells using cell-penetrating peptides. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] US Patent Application Publication No. 2022 / 0387601 [Patent Document 2] US Patent Application Publication No. 2022 / 0364085 [Patent Document 3] US Patent Application Publication No. 2022 / 0364084 Summary of the Invention [Problem to be solved by the invention]

[0005] As described above, cell membrane-permeable peptides are used as tools for introducing foreign substances such as nucleic acids into cells, and there is a demand for improving the efficiency of such introduction. [Means for solving the problem]

[0006] The present disclosure provides a peptide fragment (synthetic peptide) having cell membrane permeability. In one embodiment, the peptide fragment comprises the amino acid sequence: RRRRSNRRG (SEQ ID NO: 1) and has a total of 10 or less amino acid residues. In a preferred embodiment, the peptide fragment consists of the amino acid sequence: RRRRSNRRG (SEQ ID NO: 1). A peptide fragment containing the amino acid sequence shown in SEQ ID NO: 1 exhibits excellent cell membrane permeability, and therefore a construct containing the peptide fragment is introduced from the outside of a cell to the inside of a cell (at least into the cytoplasm).

[0007] The present disclosure also provides a construct for introducing a foreign substance (hereinafter, simply referred to as a "construct") that can introduce a foreign substance of interest from the outside of a eukaryotic cell into the inside of the cell. The construct disclosed herein comprises a peptide fragment and a foreign substance bound to the N-terminus and / or C-terminus of the peptide fragment, and is composed of the amino acid sequence: RRRRSNRRG (SEQ ID NO: 1). Such constructs allow the introduction of the foreign substance from the outside of a eukaryotic cell into the inside (eg, at least the cytoplasm) of the cell.

[0008] In some embodiments, the exogenous substance is at least one organic compound selected from the group consisting of polypeptides, nucleic acids, dyes and drugs, allowing the introduction of organic compounds with diverse functions into eukaryotic cells.

[0009] In some embodiments, the foreign substance is located at the C-terminus of the peptide fragment, allowing efficient introduction of the construct into eukaryotic cells.

[0010] The present disclosure also provides a method for introducing a foreign substance of interest into at least the cytoplasm of a eukaryotic cell from the outside of the cell in vitro or in vivo. The method disclosed herein comprises the steps of (1) preparing a construct disclosed herein and (2) supplying the construct into a sample containing the eukaryotic cell of interest. This allows the foreign substance of interest to be introduced into the eukaryotic cell.

[0011] In some embodiments, the eukaryotic cell into which the construct is introduced is a mammalian cell, thereby allowing the introduction of a desired foreign substance into the mammalian cell. [Brief description of the drawings]

[0012] [Figure 1] FIG. 1 is a graph showing the mean fluorescence intensity (MFI) of each example obtained by adding the constructs of Examples 1 to 8 or FAM to the culture medium of NSC-34 cells, culturing the cells, and then analyzing the cells using a flow cytometer. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0013] Hereinafter, some embodiments of the technology disclosed herein will be described. Matters other than those specifically mentioned in this specification and necessary for carrying out the technology (for example, general matters such as methods for chemically synthesizing peptides, cell culture techniques, and preparation of constructs containing peptides or nucleic acids as components) can be understood as design matters for those skilled in the art based on conventional techniques in the fields of cell engineering, physiology, medicine, pharmacology, organic chemistry, biochemistry, genetic engineering, protein engineering, molecular biology, genetics, etc. The technology disclosed herein can be implemented based on the contents disclosed herein and the common general technical knowledge in the field. In this specification, amino acids may be represented by one-letter symbols in accordance with the nomenclature for amino acids set forth in the IUPAC-IUB guidelines. In this specification, the term "amino acid residue" includes the N-terminal amino acid and the C-terminal amino acid of a peptide chain, unless otherwise specified.

[0014] In addition, as used herein, the term "synthetic peptide" refers to a peptide (peptide fragment) whose peptide chain does not exist stably in nature independently, but is produced by artificial chemical synthesis or biosynthesis (i.e., production based on genetic engineering) and can exist stably in a given composition. Here, "peptide" is a term that refers to an amino acid polymer (including dimers, trimers, and oligomers) having one or more peptide bonds, and is not limited by the number of amino acid residues.

[0015] In addition, in this specification, the amino acid residues constituting a peptide or protein may be of either the L-form or the D-form, unless otherwise specified. In addition, in the amino acid sequences described in this specification, the left side always represents the N-terminus and the right side represents the C-terminus.

[0016] In some embodiments, the peptide fragment disclosed herein comprises the amino acid sequence: RRRRSNRRG (SEQ ID NO: 1). The peptide fragment also consists of, for example, the amino acid sequence: RRRRSNRRG (SEQ ID NO: 1). The peptide fragment disclosed herein is, for example, a synthetic peptide.

[0017] The above-mentioned Patent Documents 1 to 3 disclose a cell membrane-permeable peptide consisting of the amino acid sequence: RRRRRRG (SEQ ID NO: 2). The present inventors conducted extensive research to improve the cell membrane permeability of the cell membrane-permeable peptide, and created the peptide fragment disclosed herein. As is clear from the test examples described below, the peptide fragment disclosed herein exhibits superior cell membrane permeability to the cell membrane-permeable peptide consisting of SEQ ID NO: 2. Therefore, a construct containing the peptide fragment disclosed herein is efficiently introduced from the outside to the inside of the cell membrane of a eukaryotic cell.

[0018] The number of amino acid residues of the peptide fragment disclosed herein is not limited as long as the cell membrane permeability is not impaired. The number of amino acid residues constituting the peptide fragment may be, for example, 12 or less, 11 or less, or 10 or less.

[0019] Furthermore, the peptide fragment disclosed herein may contain a modified sequence of SEQ ID NO: 1, so long as the cell membrane permeability is not impaired. Here, the "modified sequence" refers to an amino acid sequence (modified amino acid sequence) formed by substituting, deleting and / or adding (inserting) one or several (typically two or three) amino acid residues. Typical examples of modified sequences herein include sequences resulting from conservative substitution of one, two, or three amino acid residues (so-called conservative amino acid replacement), sequences in which one, two, or three amino acid residues are added (inserted) or deleted from a given amino acid sequence, etc. Typical examples of conservative substitutions include sequences in which a basic amino acid residue is replaced with another basic amino acid residue (e.g., mutual replacement of an arginine residue with a lysine residue), etc.

[0020] The constructs disclosed herein comprise a peptide fragment disclosed herein and a foreign substance, the foreign substance being bound to the N-terminus and / or C-terminus of the peptide fragment.

[0021] The construct is designed and constructed, for example, by directly or indirectly binding (linking) a foreign substance to the N-terminus and / or C-terminus of the peptide fragment. When the peptide fragment and the foreign substance are indirectly bound, for example, a linker is disposed between the peptide fragment and the foreign substance. The linker is not particularly limited, and may be a peptidic linker or a non-peptidic linker. In addition, a peptidic linker and a non-peptidic linker may be used in combination. The method for directly or indirectly binding the peptide fragment and the foreign substance is not particularly limited, and may be carried out according to various scientific techniques known in the art.

[0022] The peptidic linker may be composed of one or more amino acid residues. The number of amino acid residues constituting the peptidic linker is not particularly limited. The number of amino acid residues constituting the peptidic linker is, for example, one or more or two or more. The number of amino acid residues constituting the peptidic linker is, for example, 10 or less or 5 or less. In some embodiments, the amino acid sequence constituting the peptidic linker is an amino acid sequence that does not cause steric hindrance and is flexible. Such a peptidic linker may include, for example, glycine, alanine, and / or serine. In some embodiments, the peptidic linker may include β-alanine.

[0023] Examples of the non-peptidic linker include, but are not limited to, an alkyl linker, a PEG (polyethylene glycol) linker, and an aminohexanoyl spacer. A crosslinker having a homobifunctional group or a heterobifunctional group may also be used as the non-peptidic linker. Examples of common functional groups that crosslinkers have include N-hydroxysuccinimide activated ester (NHS ester), maleimide, azide, and iodoacetamide. Among these, NHS ester can react and bond efficiently with amines at a neutral pH or higher. Maleimide can selectively react and bond with SH groups. For example, when a crosslinker containing maleimide is used, a cysteine ​​residue can be added as a linker to the N-terminus or C-terminus of the peptide fragment, or a peptide fragment having a cysteine ​​residue at the N-terminus or C-terminus can be prepared to easily bond the peptide fragment to the crosslinker.

[0024] Suitable crosslinkers having homobifunctional groups include N-hydroxysuccinimide (NHS), disuccinimidyl suberate (DSS), bis(sulfosuccinimidyl) suberate (BS 3 ), dithiobis(succinimidyl propionate) (DSP), dithiobis(sulfosuccinimidyl propionate) (DTSSP), ethylene glycol bis(succinimidyl succinate) (EGS), ethylene glycol bis(sulfosuccinimidyl succinate) (sulfo-EGS), disuccinimidyl tartrate (DST), disulfosuccinimidyl tartrate (sulfo-DST), etc. In particular, bis(sulfosuccinimidyl) suberate (BS 3 ) can be preferably used.

[0025] In addition, examples of suitable crosslinking agents having heterobifunctional groups include N-(6-maleimidocaproyloxy)succinimide (EMCS), m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS), succinimidyl 4-[maleimidophenyl]butyrate (SMPB), succinimidyl 4-(maleimidomethyl)cyclohexane-1-carboxylate (SMCC), N-(γ-maleimidobutyloxy)succinimide ester (GMBS), m-maleimidopropionic acid-N-hydroxysuccinimide ester (MPS), and N-succinimidyl (4-iodoacetyl)aminobenzoate (SIAB). In particular, EMCS and MBS having NHS ester and maleimide as reactive functional groups can be preferably used.

[0026] The foreign substance is not particularly limited as long as it has a molecular size and chemical properties that can be introduced into eukaryotic cells, and may be, for example, an organic compound or an inorganic compound. Organic substances include, for example, amino acids, polypeptides, nucleic acids, dyes, drugs, etc. The foreign substance may contain one type alone or two or more types. When two or more types of foreign substances are contained, two or more types of foreign substances may be bound to the N-terminus or C-terminus of the peptide fragment. In addition, one or two or more types of foreign substances may be bound to the N-terminus and C-terminus of the peptide fragment, respectively.

[0027] When the foreign substance is a polypeptide, the polypeptide (amino acid sequence) to be adopted is not particularly limited. In this specification, the term "polypeptide" refers to a polymer (including dimers, trimers, and oligomers) having a structure in which a plurality of amino acids are bound by peptide bonds. It is not limited by the number of peptide bonds (i.e., the number of amino acid residues). As a polypeptide, for example, a peptide having about 2 to 100 amino acid residues, a polypeptide having about 100 to 300 amino acid residues, or a protein (a polymeric compound typically consisting of 300 or more amino acid residues) having a relatively large number of amino acid residues may also be adopted as a foreign substance. In this field, polypeptides and proteins are not strictly distinguished from each other. There is no particular upper limit on the number of amino acid residues constituting a polypeptide; however, from the viewpoint of ease of synthesis (biosynthesis, chemical synthesis), it is preferable that the number is, for example, 1,000 or less, 600 or less, 500 or less, 400 or less, or 300 or less.

[0028] The polypeptide may be a mature or precursor (including pro- and prepro-) polypeptide involved in functions such as the development, differentiation, proliferation, canceration, homeostasis, and metabolic regulation of various cells and tissues (organs). The polypeptide may also be a polypeptide whose function is not previously known. The technology disclosed herein makes it possible to clarify the function of a polypeptide whose function is not known within a cell (in a living tissue).

[0029] For example, when the eukaryotic cells to which a foreign substance is introduced are mammalian (human or other mammalian) stem cells, it is preferable to use mature polypeptides or their precursors having various physiological activities involved in the differentiation induction of the stem cells. Here, "stem cells" include somatic stem cells, embryonic stem cells, and induced pluripotent stem cells (iPS cells). When the eukaryotic cells to which a foreign substance is introduced are cancer cells (tumor cells), it is preferable to use various polypeptides involved in the induction of apoptosis of the cancer cells (tumor cells). Alternatively, in this case, it is preferable to use polypeptides that can inhibit the suppression of the immune surveillance mechanism of the cancer cells (tumor cells). Furthermore, when the eukaryotic cells to which a foreign substance is introduced are bacteria-infected cells or virus-infected cells, it is preferable to use various polypeptides involved in the induction of apoptosis of the infected cells, polypeptides that can suppress the proliferation of bacteria or viruses in the infected cells, and polypeptides that can suppress the spread of infection of bacteria or viruses from the infected cells. As with peptide fragments, a polypeptide as a foreign substance may contain a modified amino acid sequence formed by the substitution, deletion and / or addition (insertion) of one or several amino acid residues, so long as it retains its function.

[0030] When the foreign substance is a polypeptide, for example, a peptide chain can be designed to contain the amino acid sequence constituting the polypeptide and the amino acid sequence constituting the peptide fragment, and the peptide chain can be biosynthesized or chemically synthesized to produce a construct in which the polypeptide is directly linked to the peptide fragment.

[0031] The type of nucleic acid employed as a foreign substance is not particularly limited, and may include, for example, so-called nucleic acid drugs. In this specification, "nucleic acid" refers to a polymer of nucleotides, and includes DNA, RNA, and DNA / RNA hybrids (also called DNA-RNA chimeras) that contain both DNA and RNA. In addition, "nucleic acid" is not limited by the number of bases. Nucleic acid may be single-stranded (including hairpin-type single-stranded) or double-stranded. In addition, the nucleotides that constitute the nucleic acid may contain a modified group in the phosphate moiety, sugar moiety, or base moiety. The type of nucleic acid drug is not particularly limited, and examples thereof include siRNA, miRNA, antisense, aptamer, decoy, ribozyme, CpG oligo, etc.

[0032] The type of dye employed as the foreign substance is not particularly limited. The dye may include various fluorescent dye compounds such as FAM and FITC. When the construct contains a dye, the introduction of the construct can be easily evaluated. For example, the efficiency of introduction into eukaryotic cells can be evaluated using microscopic observation (e.g., fluorescent microscopic observation), flow cytometry, immunochemical techniques (e.g., Western blot, immunocytostaining, etc.), etc.

[0033] The type of drug employed as the foreign substance is not particularly limited, and may include various organic compounds such as antitumor agents including nucleic acid-based antitumor agents such as 5-fluorouracil (5FU) and antiviral agents such as azidothymidine (AZT).

[0034] In the construct, when a foreign substance is bound to the C-terminus of the peptide fragment, it is preferable that the α-amino group of the amino acid residue on the N-terminus of the peptide fragment is acetylated. Although the detailed mechanism is unknown, the α-amino group of the amino acid on the N-terminus of many proteins in eukaryotic cells is acetylated, so that such a configuration can improve the stability of the construct in the cell.

[0035] In addition, it is preferable that the construct has an amidated amino acid residue on the C-terminus side. Amidation of the carboxyl group of an amino acid residue (typically the C-terminal amino acid residue of a peptide chain) can improve the structural stability (e.g., protease resistance) of the construct in the cytoplasm or nucleus. Amidation of the carboxyl group also improves the hydrophilicity of the construct, thereby improving the solubility of the construct in aqueous solvents. Examples of such aqueous solvents include water, various buffer solutions, physiological saline (e.g., PBS), cell culture medium, and the like. For example, in the case of a construct in which a foreign substance is bound to the N-terminus of a peptide fragment, it is preferred that the carboxyl group of the amino acid residue at the C-terminus of the peptide fragment is amidated. Also, for example, in the case in which the foreign substance is a polypeptide and such a polypeptide is bound to the C-terminus of a peptide fragment, it is preferred that the carboxyl group of the C-terminal amino acid residue of the polypeptide is amidated.

[0036] The peptide fragment or the peptide portion of the construct (polypeptide as a foreign substance, peptide fragment, and peptidic linker) can be easily produced, for example, according to a general chemical synthesis method. For example, any of the conventionally known solid-phase synthesis method or liquid-phase synthesis method may be adopted. A solid-phase synthesis method using Boc (t-butyloxycarbonyl) or Fmoc (9-fluorenylmethoxycarbonyl) as a protecting group for an amino group is preferable. That is, the above-mentioned peptide portion having a desired amino acid sequence and modified portion (N-terminal acetylation, C-terminal amidation, etc.) can be synthesized by a solid-phase synthesis method using a commercially available peptide synthesizer. Note that only a part of the peptide chain may be synthesized by the above method, for example, only a peptide fragment, or a peptide chain containing a peptide fragment and a peptidic linker portion may be synthesized.

[0037] Alternatively, the peptide fragment or the peptide portion of the construct may be biosynthesized based on genetic engineering techniques. That is, a polynucleotide (typically DNA) of a nucleotide sequence (including an ATG start codon) encoding a desired amino acid sequence is synthesized. Then, a recombinant vector having an expression gene construct consisting of the synthesized polynucleotide (DNA) and various regulatory elements (including promoters, ribosome binding sites, terminators, enhancers, and various cis elements that control the expression level) for expressing the amino acid sequence in a host cell is constructed according to the host cell. This recombinant vector is introduced into a given host cell (e.g., yeast, insect cell, plant cell) by a general technique, and the host cell or a tissue or an individual containing the cell is cultured under given conditions. This allows the target peptide to be produced within the cell. The peptide portion is then isolated from the host cell (or from the medium if secreted), and the target peptide portion can be obtained by refolding, purification, etc. as necessary. In addition, the method of constructing a recombinant vector and the method of introducing the constructed recombinant vector into a host cell may be any method conventionally used in the field, and since such methods themselves do not particularly characterize the present technology, detailed explanations thereof will be omitted.

[0038] In addition, for the production of the peptide portion of the construct, for example, a fusion protein expression system can be used to efficiently produce a large amount of the peptide in a host cell. For example, a gene (DNA) encoding the amino acid sequence of the target polypeptide is chemically synthesized, and the synthetic gene is introduced into a suitable site of a suitable fusion protein expression vector (for example, a GST (Glutathione S-transferase) fusion protein expression vector such as the pET series provided by Novagen and the pGEX series provided by Amersham Biosciences). Then, a host cell (typically Escherichia coli) is transformed with the vector. The obtained transformant is cultured to prepare the target fusion protein. Then, the protein is extracted and purified. Then, the obtained purified fusion protein is cleaved with a specific enzyme (protease), and the released target peptide fragment (i.e., the designed artificial polypeptide) is recovered by a method such as affinity chromatography. The target polypeptide (artificial polypeptide) can be produced by using such a conventionally known fusion protein expression system (for example, the GST / His system provided by Amersham Biosciences can be used). Alternatively, a template DNA for a cell-free protein synthesis system (i.e., a synthetic gene fragment containing a nucleotide sequence encoding the amino acid sequence of the peptide portion of the construct) can be constructed, and various compounds (ATP, RNA polymerase, amino acids, etc.) necessary for the synthesis of the peptide portion can be used to synthesize the desired peptide portion in vitro using a so-called cell-free protein synthesis system. For cell-free protein synthesis systems, for example, Shimizu et al.'s paper (Shimizu et al., Nature Biotechnology, 19, 751-755(2001)) and Madin et al.'s paper (Madin et al., Proc. Natl. Acad. Sci. USA, 97(2), 559-564(2000)) can be used as reference. Based on the techniques described in these papers, many companies are already contracted to produce polypeptides at the time of filing of this application, and cell-free protein synthesis kits (available, for example, from Cell Free Science Co., Ltd. in Japan) are commercially available.

[0039] A single-stranded or double-stranded polynucleotide containing a nucleotide sequence encoding the peptide portion of the construct and / or a nucleotide sequence complementary thereto can be easily produced (synthesized) by a conventional method. For example, by selecting a codon corresponding to the amino acid residue constituting the peptide portion, a nucleotide sequence corresponding to the amino acid sequence can be easily determined and provided. Once the nucleotide sequence is determined, a polynucleotide (single-stranded) corresponding to the desired nucleotide sequence can be easily obtained using a DNA synthesizer or the like. Furthermore, the desired double-stranded DNA can be obtained by employing various enzymatic synthesis means (typically PCR) using the obtained single-stranded DNA as a template. The polynucleotide may be in the form of DNA or in the form of RNA (mRNA, etc.). The DNA may be provided in a double-stranded or single-stranded form. When provided in a single-stranded form, it may be a coding strand (sense strand) or a non-coding strand (antisense strand) having a complementary sequence thereto. The polynucleotide thus obtained can be used as a material for constructing a recombinant gene (expression cassette) for peptide production in various host cells or in a cell-free protein synthesis system, as described above. The nucleic acid as the foreign substance can also be prepared in the same manner as in the above-mentioned production method.

[0040] The construct disclosed herein may be suitably used as an active ingredient of a composition for use based on the function of the foreign substance. The construct may be in the form of a salt as long as the function of the foreign substance is not lost. For example, an acid addition salt that can be obtained by addition reaction of a commonly used inorganic acid or organic acid according to a conventional method can be used. Therefore, the "construct" described in this specification and claims may include such a salt form.

[0041] The construct can be used as an active ingredient of a composition which can contain various medicamentally (pharmacologically) acceptable carriers depending on the form of use. The above-mentioned carrier is preferably a carrier generally used in peptide medicines as a diluent, excipient, etc. The carrier may vary depending on the purpose and form of the construct for introducing a foreign substance, but typically includes water, physiological buffer solutions, and various organic solvents. In addition, the carrier may be an aqueous solution of alcohol (such as ethanol) at an appropriate concentration, glycerol, a non-drying oil such as olive oil, or a liposome. In addition, examples of secondary components that may be contained in the pharmaceutical composition include various fillers, bulking agents, binders, wetting agents, surfactants, dyes, fragrances, etc.

[0042] The form of the composition is not particularly limited. For example, the composition may be in the form of a liquid, suspension, emulsion, aerosol, foam, granule, powder, tablet, capsule, ointment, etc. In addition, the composition may be in the form of a freeze-dried product or granules that are dissolved in physiological saline or a suitable buffer solution (e.g., PBS) immediately before use to prepare a drug solution for injection or the like. The process of preparing various forms of drugs (compositions) using constructs (main components) and various carriers (secondary components) may be in accordance with conventionally known methods, and detailed explanations of such formulation methods are omitted since they do not characterize the present technology. For example, Comprehensive Medicinal Chemistry, edited by Corwin Hansch, published by Pergamon Press (1990) is an example of a detailed information source regarding formulations.

[0043] The present disclosure provides a method for introducing a foreign substance of interest from the outside of a eukaryotic cell into the inside of the cell in vivo or in vitro using the construct disclosed herein. Here, "inside a eukaryotic cell" refers to the inside of a eukaryotic cell surrounded by a cell membrane, and includes, for example, the cytoplasm, cytosol, and intracellular organelles (e.g., nucleus, mitochondria, endoplasmic reticulum, microtubules, lysosomes, Golgi, etc.). In the method disclosed herein, for example, a construct can be introduced into at least the cytoplasm (and even intracellular organelles) of a eukaryotic cell.

[0044] The method disclosed herein roughly comprises the following steps (1) and (2): (1) providing a construct as disclosed herein; (2) providing the construct into a sample containing a eukaryotic cell of interest; The method disclosed herein may further include, after the above step (2), a step (3) of incubating the sample containing the construct to introduce the construct into eukaryotic cells in the sample.

[0045] The above-mentioned "eukaryotic cells" include, for example, various tissues, organs, blood, and lymphatic fluids in vivo. The above-mentioned "eukaryotic cells" include, for example, various cell masses, tissues, organs, blood, and lymphatic fluids, as well as cell lines, etc., extracted from living organisms in vitro. Examples of eukaryotic cells include cells derived from the animal kingdom, such as mammals, birds, fish, amphibians, reptiles, and insects, cells derived from the fungus kingdom, and cells derived from the plant kingdom, and are preferably cells of humans or mammals other than humans (mammalian cells).

[0046] The methods disclosed herein include, for example, preparing a composition comprising a construct disclosed herein. , and is supplied into a sample containing eukaryotic cells. In vivo, such a composition can be used in a manner and dosage depending on its form and purpose. For example, as a liquid agent, it can be administered in a desired amount to an affected area (e.g., malignant tumor tissue, virus-infected tissue, inflammatory tissue, etc.) of a patient (i.e., a living body) by intravenous, intramuscular, subcutaneous, intradermal, or intraperitoneal injection. Alternatively, a solid form such as a tablet or a gel or aqueous jelly such as an ointment can be directly administered to a predetermined tissue (i.e., an affected area such as a tissue or organ containing, for example, tumor cells, virus-infected cells, inflammatory cells, etc.). Alternatively, a solid form such as a tablet can be administered orally. In the case of oral administration, it is preferable to encapsulate or apply a protective (coating) material to suppress digestive enzyme decomposition in the digestive tract.

[0047] In vitro, an appropriate amount of the construct or composition may be supplied to the culture medium of the eukaryotic cells being cultured at least once. The amount and number of times of supply per time are not particularly limited because they may vary depending on the type of eukaryotic cells to be cultured, cell density (cell density at the start of culture), number of passages, culture conditions, type of medium, and other conditions. For example, it is preferable to add once, twice, or more times so that the peptide fragment concentration in the culture medium is generally within the range of 0.05 μM to 100 μM, for example, within the range of 0.5 μM to 50 μM, and for example, within the range of 1 μM to 30 μM. In addition, the incubation time after addition of the construct is also not particularly limited because it may vary depending on the type of eukaryotic cells and various conditions. For example, it may be 0.5 hours or more, 1 hour or more, 4 hours or more, 8 hours or more, or 20 hours or more. In addition, the incubation conditions are not particularly limited because they may vary depending on the type of eukaryotic cells, but for example, it can be incubated in a 5% CO2 atmosphere at 37°C. An example of an in vitro introduction method is shown in the test example described below.

[0048] As described above, specific aspects of the technology disclosed herein include those described in the following sections. Item 1: A peptide fragment comprising the amino acid sequence: RRRRSNRRG (SEQ ID NO:1) and having a total of 10 or less amino acid residues. Item 2: The peptide fragment according to Item 1, which consists of the amino acid sequence: RRRRSNRRG (SEQ ID NO: 1). Item 3: A construct comprising a peptide fragment and a foreign substance bound to the N-terminus and / or C-terminus of the peptide fragment, wherein the peptide fragment has the amino acid sequence: RRRRSNRRG (SEQ ID NO: 1). Item 4: The construct according to Item 3, wherein the foreign substance is at least one organic compound selected from the group consisting of a polypeptide, a nucleic acid, a dye, and a drug. Item 5: The construct according to Item 3 or 4, wherein the foreign substance is bound to the C-terminus of the peptide fragment. Item 6: A method for introducing a foreign substance of interest from the outside of a eukaryotic cell into the inside of the cell in vitro, comprising: (1) preparing a construct according to any one of items 3 to 5; (2) providing the construct into a sample containing a eukaryotic cell of interest; The method includes: Item 7: The method according to Item 6, wherein the eukaryotic cell into which the construct is introduced is a mammalian cell.

[0049] Several test examples relating to the technology disclosed herein will be described below, but it is not intended that the technology disclosed herein be limited to those shown in these test examples.

[0050] <Preparing the construct> In Examples 1 to 8, constructs shown in Table 1 were prepared. As shown in Table 1, in each Example, a peptide fragment (synthetic peptide) consisting of any one of SEQ ID NOs: 1 to 8 and a fluorescent dye FAM (C 21 H 12 A construct consisting of O7:5(6)-Carboxyfluorescein (molecular weight 376.3, excitation wavelength 495 nm, fluorescence wavelength 520 nm) was prepared. In each example, the amino group of the N-terminal amino acid residue of the peptide fragment was acetylated. Each construct was dissolved in dimethyl sulfoxide (DMSO) to prepare a sample solution with a construct concentration of 2 mM. A 2 mM FAM solution was prepared by dissolving the fluorescent dye FAM in DMSO. Hereinafter, for the sake of explanation, the construct used in Example X will be referred to as construct X, and the sample solution as sample solution X.

[0051] <Evaluation of cell membrane permeability> The cell membrane permeability of the above-prepared constructs was evaluated using NSC-34 cells (mouse motor neuron-like hybrid cell line) as eukaryotic cells.

[0052] (Example 1) NSC-34 cells were cultured in a culture medium, Dulbecco's modified Eagle's medium (DMEM, manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., Cat No. 044-29765), containing 10% FBS (fetal bovine serum). After washing the NSC-34 cells attached to the culture plate with PBS, a 0.25% trypsin / EDTA solution was added and incubated at 37°C for 3 minutes. After the incubation, the above-mentioned 10% FBS-containing DMEM was added to inactivate the trypsin, and the cells were precipitated by centrifugation at 150 x g for 5 minutes. After removing the supernatant generated by centrifugation, the above-mentioned 10% FBS-containing DMEM was added to the precipitate (cell pellet), and approximately 2 x 10 5 A cell suspension of 10 cells / mL was prepared. 1 mL of the cell suspension was added to a well of a commercially available 6-well plate (AGC Technoglass Co., Ltd.), and the cells were seeded (approximately 2 × 10 5 cells / well) and incubated for 2 to 3 hours until the cells attached to the bottom of the well. Then, the 2 mM sample solution 1 prepared above was diluted with the 10% FBS-containing DMEM to prepare a sample solution 1 with a sample concentration of 20 μM. Then, 1 mL of the 20 μM sample solution 1 was added to the well (i.e., the concentration of construct 1 in the culture solution in the well was 10 μM and the DMSO concentration was 0.5%). The cells were incubated at 37°C under 5% CO2 conditions for 20 hours.

[0053] After 20 hours of incubation, the culture supernatant was removed from the well, and the cells in the well were washed twice with 1 mL of PBS. Next, 100 μL of 0.25% trypsin / EDTA solution was added to the well, and the well was incubated at 37° C. for 3 minutes. After the incubation, 900 μL of the above 10% FBS-containing DMEM was added to the well to inactivate trypsin, and the cell suspension in the well was transferred to a tube to recover the cells. After that, the cells remaining in the well were further washed and recovered into the tube. This tube was centrifuged for 5 minutes at 4° C. and 210×g. After centrifugation, the supernatant was removed, and the precipitate (cell pellet) was suspended (washed) in 1 mL of PBS, and centrifuged under the same conditions as above. Then, the supernatant was removed to obtain cells (cell pellet) cultured in the construct-containing medium.

[0054] The obtained cells (cell pellets) were analyzed for cell membrane permeability using a flow cytometer, On-Chip Flowcytometer (On-Chip Biotechnologies Co., LTD.). For such analysis, the cell pellet obtained above was suspended in 50 μL of On-chip T buffer to prepare a cell suspension for analysis.

[0055] Using the above flow cytometer, gating based on forward scatter (FSC) and side scatter (SSC) was performed, a gate was set for the cell population to be analyzed, and the fluorescence intensity of the cell population within the gate was measured. The number of cells in the cell population to be analyzed was set to about 10,000, and the analysis was performed. The fluorescence intensity was measured using the fluorescence detector FL2 (optimum detection wavelength: about 543 nm) of the above flow cytometer, which can detect the fluorescence wavelength of FAM. The measurement results were analyzed using a commercially available analysis software "FlowJo" (manufactured by TreeStar), and the mean fluorescence intensity (MFI) of the cell population to be measured was obtained.

[0056] (Examples 2 to 8) Examples 2 to 8 were carried out in the same manner as in Example 1, except that sample solution 1 was replaced with one of sample solutions 2 to 8.

[0057] (Example 9) Example 9 was carried out in the same manner as Example 1, except that an FAM solution was used instead of sample solution 1. The concentration of the FAM solution was the same as that of sample solution 1 (i.e., the FAM concentration of the culture solution in the well was 10 μM, and the DMSO concentration was 0.5%).

[0058] The MFI results obtained in Examples 1 to 9 are shown in Table 1 and FIG.

[0059] [Table 1]

[0060] As described above, the peptide fragment contained in the construct used in Example 8 is a cell membrane-permeable peptide disclosed in Patent Documents 1 to 3, etc. In this test, SN (serine-asparagine residue) was added or inserted to the end or between amino acid residues of this peptide fragment, and cell membrane permeability was evaluated. As a result, as shown in Table 1 and FIG. 1, it was surprisingly found that the construct containing the peptide fragment consisting of the amino acid sequence RRRRSNRRG used in Example 5 exhibited particularly excellent cell membrane permeability.

[0061] Although detailed data is not shown, the inventors' studies have confirmed that a construct containing a peptide fragment consisting of the amino acid sequence RRRRSNRRG and a polypeptide, nucleic acid, or drug as a foreign substance can be efficiently introduced from the outside of a eukaryotic cell into the inside of the cell.

[0062] Although specific examples of the technology disclosed herein have been described in detail above, these are merely examples and do not limit the scope of the claims. The technology described in the claims includes various modifications and alterations of the specific examples exemplified above.

[0063] According to the present disclosure, a peptide fragment capable of introducing a foreign substance of interest from the outside of a eukaryotic cell (particularly various animal cells not having a cell wall, such as human cells and other mammalian cells) to the inside of the cell and a construct having the peptide fragment are provided. By using such a construct, a foreign substance of interest can be effectively introduced into a cell of interest, and a living tissue such as a cell or an organ into which the foreign substance has been introduced can be obtained. Furthermore, the peptide fragment or construct disclosed herein can be used in a drug delivery technique to provide a therapeutic agent for various diseases (e.g., a therapeutic agent for ophthalmic treatment, etc.). Furthermore, the peptide fragment or construct disclosed herein can be used as an active ingredient or additive of an external medicine (e.g., eye drops, etc.).

Claims

1. Contains the amino acid sequence: RRRRSNRRG (SEQ ID NO:1), The total number of amino acid residues is 10 or less. Peptide fragments.

2. 2. The peptide fragment of claim 1, consisting of the amino acid sequence: RRRRSNRRG (SEQ ID NO:1).

3. A peptide fragment, A foreign substance bound to the N-terminus and / or C-terminus of the peptide fragment. A construct comprising: The peptide fragment consists of the amino acid sequence: RRRRSNRRG (SEQ ID NO:1); Construction.

4. The construct of claim 3 , wherein the exogenous substance is at least one organic compound selected from the group consisting of polypeptides, nucleic acids, dyes and drugs.

5. The construct according to claim 4 , wherein the foreign substance is bound to the C-terminus of the peptide fragment.

6. A method for introducing a foreign substance of interest from the outside of a eukaryotic cell to the inside of the cell in vitro, comprising the steps of: (1) providing a construct according to any one of claims 3 to 5; (2) providing the construct in a sample containing a eukaryotic cell of interest; The method includes:

7. The method of claim 6, wherein the eukaryotic cell into which the construct is introduced is a mammalian cell.

Citation Information

Patent Citations

  • Exon skipping oligomers for muscular dystrophy

    US20220364084A1

  • Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene

    US20220364085A1

  • Exon skipping oligomer conjugates for muscular dystrophy

    US20220387601A1